Inactivation of TGFβ receptors in stem cells drives cutaneous squamous cell carcinoma.
journal contributionposted on 11.11.2016, 12:34 by P. Cammareri, A. M. Rose, D. F. Vincent, J. Wang, A. Nagano, S. Libertini, R. A. Ridgway, D. Athineos, P. J. Coates, A. McHugh, C. Pourreyron, J. H. S. Dayal, J. Larsson, S. Weidlich, L. C. Spender, G. P. Sapkota, K. J. Purdie, C. M. Proby, C. A. Harwood, I. M. Leigh, H. Clevers, N. Barker, S. Karlsson, Catrin Pritchard, R. Marais, C. Chelala, A. P. South, O. J. Sansom, G. J. Inman
Melanoma patients treated with oncogenic BRAF inhibitors can develop cutaneous squamous cell carcinoma (cSCC) within weeks of treatment, driven by paradoxical RAS/RAF/MAPK pathway activation. Here we identify frequent TGFBR1 and TGFBR2 mutations in human vemurafenib-induced skin lesions and in sporadic cSCC. Functional analysis reveals these mutations ablate canonical TGFb Smad signalling, which is localized to bulge stem cells in both normal human and murine skin. MAPK pathway hyperactivation (through BrafV600E or KrasG12D knockin) and TGFb signalling ablation (through Tgfbr1 deletion) in LGR5 þ ve stem cells enables rapid cSCC development in the mouse. Mutation of Tp53 (which is commonly mutated in sporadic cSCC) coupled with Tgfbr1 deletion in LGR5 þ ve cells also results in cSCC development. These findings indicate that LGR5 þ ve stem cells may act as cells of origin for cSCC, and that RAS/RAF/MAPK pathway hyperactivation or Tp53 mutation, coupled with loss of TGFb signalling, are driving events of skin tumorigenesis